Division of Pediatrics Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Gut. 2018 May;67(5):963-972. doi: 10.1136/gutjnl-2017-315691. Epub 2018 Jan 24.
A subset of patients with non-alcoholic fatty liver disease develop an inflammatory condition, termed non-alcoholic steatohepatitis (NASH). NASH is characterised by hepatocellular injury, innate immune cell-mediated inflammation and progressive liver fibrosis. The mechanisms whereby hepatic inflammation occurs in NASH remain incompletely understood, but appear to be linked to the proinflammatory microenvironment created by toxic lipid-induced hepatocyte injury, termed lipotoxicity. In this review, we discuss the signalling pathways induced by sublethal hepatocyte lipid overload that contribute to the pathogenesis of NASH. Furthermore, we will review the role of proinflammatory, proangiogenic and profibrotic hepatocyte-derived extracellular vesicles as disease biomarkers and pathogenic mediators during lipotoxicity. We also review the potential therapeutic strategies to block the feed-forward loop between sublethal hepatocyte injury and liver inflammation.
一部分非酒精性脂肪性肝病患者会发展成一种炎症状态,称为非酒精性脂肪性肝炎(NASH)。NASH 的特征是肝细胞损伤、固有免疫细胞介导的炎症和进行性肝纤维化。NASH 中肝炎症发生的机制尚不完全清楚,但似乎与由毒性脂质诱导的肝细胞损伤引起的促炎微环境有关,称为脂毒性。在这篇综述中,我们讨论了亚致死性肝细胞脂质过载诱导的信号通路,这些通路导致了 NASH 的发病机制。此外,我们将回顾促炎、促血管生成和促纤维化的肝细胞衍生细胞外囊泡作为脂毒性期间疾病生物标志物和致病介质的作用。我们还回顾了阻断亚致死性肝细胞损伤与肝脏炎症之间正反馈循环的潜在治疗策略。